BioCryst Pharmaceuticals BCRX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

BridgeBio PharmaBBIO

$18.66M+84.3%

Agios PharmaceuticalsAGIO

$31.17M-36.1%

PrecigenPGEN

$4.73M-12.7%

AnaptysBio, Inc.ANAB

$13.61K-99.9%

Acadia PharmaceuticalsACAD

$73.85M+31.2%

Aquestive Therapeutics, Inc.AQST

$4.82M-10.1%

FAQ

What is BioCryst Pharmaceuticals's operating lease liabilities (total)?

BioCryst Pharmaceuticals (BCRX) reported operating lease liabilities (total) of $12.52M in Q2 2026.

How has BioCryst Pharmaceuticals's operating lease liabilities (total) changed year-over-year?

BioCryst Pharmaceuticals's operating lease liabilities (total) increased by 40.9% year-over-year, from $8.88M to $12.52M.

What is the long-term trend for BioCryst Pharmaceuticals's operating lease liabilities (total)?

Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's operating lease liabilities (total) has grown at a 12.0% compound annual growth rate (CAGR), from $5.05M to $8.89M.

What does operating lease liabilities (total) mean?

This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.